

(a) determining the expression of a gene at least 90% identical to SEQ ID NO:1 in a first sample from a first individual; and

(b) comparing said expression of said gene in the first sample, to the expression of said gene in a second sample, said second sample from a second normal tissue type from said first individual, or from a second, unaffected individual;

wherein a difference in said expression of said gene between the first sample and the second sample indicates that the first individual has colorectal cancer.

C, 33. (New) The method of claim 32, wherein the expression of said gene in said first sample from said first individual is up-regulated by comparison to expression of said gene in said second sample.

34. (New) The method of claim 32, wherein said second sample is from said first individual.

35. (New) The method of claim 32, wherein said first sample is colorectal tissue.

36. (New) The method of claim 32, wherein said second sample is colorectal tissue.

37. (New) The method of claim 32, wherein said first sample is a blood sample.

38. (New) The method of claim 32, wherein said expression is measured using a binding agent.

39. (New) The method of claim 38, wherein the binding agent is detectably labeled.